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The American Cancer Society estimates that in 2021 60,430 individuals will be diagnosed 
with pancreatic cancer and 48,220 individuals will die from the cancer. Pancreatic ductal 
adenocarcinoma (PDAC) has a 5-year survival rate of 9% largely due to the typical detection at an 
advanced stage. Initiatives in the field of oncology have focused on the importance of detection of 
cancer at an early stage. Genetics plays a role in early detection through the identification of a 
genetic predisposition to cancer. Approximately 10% of PDAC diagnoses are due to a germline 
pathogenic variant. Identification of a pathogenic variant can have implications for both the patient 
and their family members. PDAC is part of several hereditary cancer predisposition syndromes 
and genes that cause increased risk for multiple cancer types and have specific guidelines to 
increase early detection or reduce the risk for some cancers. Pathogenic variants in certain genes 
are compatible with precision therapies that can aid in treatment of PDAC.  
The National Comprehensive Cancer Network (NCCN) and American Society for Clinical 
Oncology (ASCO) recommend that all individuals with PDAC have a genetic evaluation and 
consider germline genetic testing. Ideally, this should be done by a genetic counselor who 
specializes in cancer genetic counseling. However, there continues to be a nationwide shortage of 
genetic counselors. This has led to development of alternative service delivery methods. 
University of Pittsburgh Medical Center (UPMC) created a short educational video about 
the genetics of pancreatic cancer in effort to increase access to germline genetic testing. This study 
 v 
aimed to assess the effectiveness and patient satisfaction of this delivery method of genetic 
information. Two delivery methods were compared; video education and traditional in-person 
genetic counseling for individuals diagnosed with PDAC. Genetic literacy was evaluated prior to 
education and knowledge and satisfaction were assessed immediately following the genetics 
education. For individuals who pursued genetic testing, knowledge was assessed at an additional 
timepoint.     
While this study focuses on genetic counseling, these research findings are relevant to the 
field of public health as it could provide baseline information advising the use of video education 
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The goal of this study was to build upon a previous pilot study which evaluated the use of 
video education for individuals with pancreatic ductal adenocarcinoma (PDAC). The pilot study 
evaluated pancreatic cancer knowledge between a group who received traditional genetic 
counseling and a group who watched an educational video. This study was continued with the 
additional evaluation component of patient satisfaction with each delivery method. 
Pancreatic ductal adenocarcinoma is an aggressive cancer with poor early detection. 
Approximately 10% of individuals with pancreatic cancer harbor a pathogenic variant in a 
pancreatic cancer susceptibility gene.1 Identification of a pathogenic variant can have implications 
for oncologic treatment and for family members of an affected individual. The American Society 
of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) recommend 
that all individuals with pancreatic cancer undergo risk assessment for a hereditary predisposition 
to cancer.2,3 This recommendation can be difficult to fulfill as there is a shortage of genetic 
counselors available who can provide counseling for pancreatic cancer in a short time frame that 
adapts to the limited survival rate of PDAC and need of information for potential treatment 
implications.4 The barrier to genetic evaluation highlights the need to explore alternative methods 
of service delivery. 
University of Pittsburgh Medical Center (UPMC) created a multidisciplinary clinic (MDC) 
for individuals newly diagnosed with pancreatic cancer through which they can meet with all 
necessary specialists in one appointment. This structure includes a genetics consultation and 
subsequent research-based evaluation of delivery methods. The UPMC MDC takes place in two 
medical centers, Hillman Cancer Center and Presbyterian Hospital. A 5-minute video explaining 
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the genetics related to pancreatic cancer and genetic testing was developed as an alternative method 
of delivering genetics education.  
The pilot study which began in January 2020 was continued as a comparison of participant 
genetic knowledge between a group who received traditional genetic counseling with an in-person 
certified genetic counselor and a group who watched the educational video. The specific aim of 
this study was to determine if the use of video education is a practical and effective way to 
deliver information about genetic testing for individuals with pancreatic ductal 
adenocarcinoma. 
An additional aim which began in September 2020, was implemented as a comparison of 
patient satisfaction with their designated method of receiving genetic education about pancreatic 
cancer. The specific aim of this study was to assess patient satisfaction with receiving genetics 
education about pancreatic cancer and genetic testing through video education.  
These aims were evaluated through administration of questionnaires to patients in-person 
during their MDC appointment before and after receiving genetics education, and then at an 
additional timepoint for follow-up. The overall goal of this study was to examine the use of pre-
recorded video education material to evaluate the effectiveness and satisfaction of this method of 
providing genetic information. While this study focused on genetic counseling for pancreatic 
cancer, these research findings are relevant to the overall field of genetic counseling. Findings 
from this study could provide information pertaining to the use of video education as an effective 
and satisfactory method of genetic information delivery in other cancer genetic counseling settings 
in the future. 
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2.0 Literature Review 
2.1 Pancreatic Cancer 
Pancreatic cancer is considered a rare and aggressive form of cancer. In 2018, there were 
458,918 reported cases of pancreatic cancer globally, and 432,242 deaths.1 While the United States 
has made significant advancements in the treatment and management of cancer, pancreatic cancer 
remains the third most common cause of cancer-related deaths in the United States, with a 5-year 
survival rate of 9%.1 The annual report from the American Cancer Society estimates that in 2021, 
60,430 individuals will be diagnosed with pancreatic cancer and that 48,220 deaths will occur as 
a result of the cancer.5 
One of the reasons for the high mortality rate of pancreatic cancer is the limited options for 
surgical treatment when diagnosed at an advanced stage. Less than 20% of pancreatic cancers are 
resectable when diagnosed, and those which are resectable often still result in micrometatastes. 
Unlike other types of cancer, pancreatic cancer typically does not manifest symptoms until it is at 
an advanced stage and the presenting symptoms are relatively non-specific to pancreatic cancer. 
These symptoms include abdominal pain, jaundice, pruritis, and darkened urine. Patients also 
usually present with weight loss and lack of appetite.1 These symptoms overlap with other less 
severe types of gastrointestinal conditions, which can often delay proper diagnosis.  
Another reason for the difficulty in identifying pancreatic cancer is the lack of screening 
for pancreatic in the general population. Currently, the International Cancer of the Pancreas 
(CAPS) Consortium only recommends surveillance for individuals in the high-risk population 
given the limitations in efficacy of these methods in the general population.6  The current practice 
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in place for pancreatic cancer surveillance is annual imaging of the pancreas by either MRI with 
magnetic resonance cholangiopancreatography (MRCP) or endoscopic ultrasound (EUS).6  
The concept of universal screening for pancreatic cancer in the general population has been 
discussed, however there are several issues with this practice. While extremely lethal, pancreatic 
cancer is a rare form of cancer. Because it is a rare cancer, universal screening would result in 
unnecessary cost and invasive procedures for most of the population. Additionally, pancreatic 
cancer screening yields a relatively high number of false positives.7 In a study of the efficacy of 
pancreatic cancer screening, in 367 subjects who underwent an EUS-FNA, nearly 4% presented 
with a false-positive detection of a solid pancreatic finding as malignant.8  
2.2 Pancreatic Cancer Risk Factors 
There are many risk factors associated with pancreatic cancer. These risk factors fall into 
two categories: modifiable and non-modifiable. Modifiable risk factors are defined as risk factors 
that can be changed or eliminated. Modifiable risk factors associated with pancreatic cancer 
include tobacco use, obesity, and environmental exposures.1 Acquired conditions of diabetes and 
chronic pancreatitis are also risk factors for pancreatic cancer.1 Tobacco use is the strongest risk 
factor associated with pancreatic cancer, with a nearly 75% increased risk for pancreatic cancer in 
active smokers.9 Additionally, an approximate 20% increased risk for pancreatic cancer persists in 
former smokers for 10 to 20 years following smoking cessation.10 
Obesity and diabetes are also significant risk factors for pancreatic cancer. While the 
mechanism of association between obesity and pancreatic cancer is not entirely understood, studies 
show that obese individuals have a 50% increase in risk for pancreatic cancer as compared to the 
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general population.11 Obesity often presents in conjunction with type 2 diabetes mellitus. Several 
studies have shown that the risk for pancreatic cancer is nearly twice as high in individuals with 
type 2 diabetes.11 However, the relationship between pancreatic cancer and diabetes is complex 
and demonstrates “dual-causality.” Longstanding type 2 diabetes causes prolonged periods of high 
intrapancreatic insulin levels that adversely affect the pancreas and increases the risk for 
development of adenocarcinoma. Conversely, pancreatic cancer can contribute to exocrine 
insufficiency which can result in pancreatogenic diabetes.12 Many research studies have aimed to 
better understand this relationship through evaluation of clinical features, biomarkers, and time of 
onset of diabetes in individuals with and without pancreatic cancer.13 Determining the initial 
condition as diabetes or adenocarcinoma can add a vital component to early detection of pancreatic 
cancer.12 The two risk factors of diabetes and obesity are of further concern as the incidence of 
these conditions continues to substantially increase in the United States population.  
In addition to modifiable and acquired risk factors for pancreatic cancer, there are also a 
number of non-modifiable risk factors. These include conditions or features that cannot be changed 
or that individuals have beginning at birth. Non-modifiable risk factors associated with pancreatic 
cancer include age, sex, race, blood group, family history, and genetic predisposition including 
hereditary syndromes associated with increased risk for developing pancreatic cancer. Pancreatic 
cancer is considered a disease of aging. Approximately 90% of cases occur in individuals over 55, 
with the majority of those cases in people over 70 years of age.10 Males are also at a slightly 
increased risk to develop pancreatic cancer as compared to females. Studies suggest that this 
discrepancy in gender is more likely a product of environmental and lifestyle influences as opposed 
to physiology.1 Pancreatic cancer is noted to have a higher prevalence in certain ethnic populations, 
the highest of which is in African Americans. It has been suggested that the higher prevalence is 
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related to environmental and lifestyle factors.10 However, other research indicates there may be 
underlying genetic influences that could be responsible for the increased prevalence in the African-
American population.1 Blood group has also been identified as a contributing risk factor for 
pancreatic cancer. Data analyses have shown that the prevalence of pancreatic cancer is higher in 
individuals with type A, B, or AB blood as opposed to type O due to the difference in glycoproteins 
found on the surface of cells.14 
The last important group of non-modifiable risk factors includes family history and genetic 
susceptibility. Familial pancreatic cancer or the presence a pathogenic variant in a pancreatic 
cancer susceptibility gene results in an increased risk for an individual to develop pancreatic 
cancer. These hereditary causes of pancreatic cancer account for approximately 10% of cases of 
pancreatic cancer.1 
2.3 Genetic Associations with Pancreatic Cancer 
Research has revealed that there are several genes and familial syndromes associated with 
an increased risk for pancreatic cancer (Table 1). The American Society of Clinical Oncology 
(ASCO) recommends that all individuals with pancreatic adenocarcinoma undergo risk assessment 
for a hereditary predisposition associated with an increased risk for pancreatic cancer.2 Beginning 
with version 1.2019, National Comprehensive Cancer Network (NCCN) guidelines included 
personal history of pancreatic adenocarcinoma as an indication for germline genetic testing.3 The 
current recommendation is for all individuals with pancreatic cancer to have panel testing which 
includes genes that have been suggested to be associated with an increased risk for pancreatic 
cancer. 
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To date, there are six hereditary cancer syndromes and two additional genes that are known 
to be associated with an increased risk for pancreatic cancer.15 Hereditary Breast and Ovarian 
Cancer (HBOC) remains one of the most well-defined cancer predisposition syndromes with a 
substantial increase in risk for breast and ovarian cancer in women, as well as moderately increased 
risks for male breast cancer, prostate cancer, melanoma, and pancreatic cancer. HBOC is caused 
by pathogenic variants in the BRCA1 and BRCA2 genes. Pathogenic variants in BRCA1 and BRCA2 
increase the risk for pancreatic cancer to 1-3% and 2-7%, respectively.16  
Familial Atypical Multiple Mole Melanoma (FAMMM) is an autosomal dominant cancer 
predisposition syndrome characterized by multiple melanocytic nevi and an increased risk for 
melanoma and pancreatic cancer. This condition is caused by pathogenic variants in the CDKN2A 
gene.17 The most recent data indicate the risk for pancreatic cancer associated with a CDKN2A 
pathogenic variant is 17% by age 75.17 The association of pancreatic cancer and melanoma has a 
strong genetic cause. A study of the world’s largest familial melanoma database revealed that 74% 
of families with pancreatic cancer and melanoma had a CDKN2A pathogenic variant.17 
Peutz-Jeghers syndrome is a hereditary cancer syndrome associated with the highest 
lifetime risk for pancreatic cancer. Peutz-Jeghers syndrome is an autosomal dominant condition 
caused by pathogenic variants in the STK11 gene. It is characterized by hamartomatous polyps of 
the gastrointestinal tract and mucocutaneous hyperpigmentation.18 The types of cancer with the 
highest increased risk in Peutz-Jeghers syndrome are colorectal, breast, stomach, and pancreatic 
cancer. A meta-analysis of 210 individuals with an STK11 germline pathogenic variant revealed a 
132-fold increased risk for pancreatic cancer. This equates to a 32% lifetime risk for pancreatic 
cancer.18 However, Peutz-Jeghers syndrome has a relatively low prevalence in the general 
population and is often times identified at younger ages due to the associated physical features.  
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Lynch syndrome is a hereditary cancer predisposition syndrome characterized by a 
significantly increased risk for colon cancer and endometrial cancer. There is also an increased 
risk for stomach, ovarian, small bowel, urinary tract, brain, and pancreatic cancer. The risk for 
pancreatic cancer is around 8.6 times that of the general population, with a lifetime risk of 3.7%.19 
Lynch syndrome is caused by a pathogenic variant in any of four mismatch repair genes; MLH1, 
MSH2, MSH6, and PMS2, as well as EPCAM. Pancreatic cancer characteristic of Lynch syndrome 
is often medullary type and invades into lymph nodes.19  
Familial Adenomatous Polyposis (FAP) is an autosomal dominant inherited cancer 
syndrome caused by pathogenic variants in the APC gene. FAP causes the development of tens to 
thousands of colorectal adenomas, resulting in a 100% risk of colon cancer without intervention.15 
There is also an increased risk of approximately 2% for pancreatic cancer and thyroid cancer.20 
There are several studies that suggest an additional increased frequency of intraductal papillary 
and mucinous neoplasms (IPMN) in individuals with FAP. One case review describes a 48-year-
old male who underwent a colectomy with ileorectal anastomosis in his youth due to a clinical 
diagnosis of FAP. He was later found to have an IPMN with loss of heterozygosity in the tumor. 
Germline testing revealed a pathogenic variant in the APC gene.20 
Li-Fraumeni Syndrome is a severe hereditary cancer predisposition syndrome caused by 
germline pathogenic variants in the TP53 gene. The TP53 gene creates a protein that is a master 
regulator of the cell cycle. Somatic mutations of TP53 are the most commonly seen alterations in 
tumors, occurring in around 50% of tumors.21 Conversely, germline pathogenic variants in TP53 
are rare in the general population. Germline pathogenic variants cause an increased risk for a wide 
spectrum of early-onset cancers. These most commonly include breast, sarcoma, adrenocortical, 
and brain cancers.22 The exact risk for pancreatic cancer in a TP53 pathogenic variant is unknown. 
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However, in a study of 24 individuals with a TP53 pathogenic variant, there was an increased 
relative risk for pancreatic cancer as compared to that of the general population.23 
The contribution of PALB2 to germline causes of cancer is becoming more recognized. 
PALB2 is associated with a significantly increased lifetime risk of breast cancer and more recently, 
research has shown that PALB2 is also associated with an increased risk of other cancers, including 
pancreatic cancer.23 The relative risk for an individual with a PALB2 pathogenic variant to develop 
pancreatic cancer is 2.37 as compared to the general population.24 PALB2 works together with the 
BRCA2 gene in the DNA repair process. One study in 2013 evaluated the presence of PALB2 and 
BRCA pathogenic variants in cases of familial breast and pancreatic cancer. Of 96 individuals with 
familial pancreatic cancer, 3.1% were found to have a pathogenic variant in PALB2.23  
ATM is another gene associated with an increased risk for pancreatic cancer and is most 
commonly associated with Ataxia Telangiectasia. Ataxia Telangiectasia is an autosomal recessive 
condition that primarily affects the nervous system and immune system causing chronic lung 
infections, slurred speech, and as per the name; ataxia and telangiectasias. More recent research 
has identified the association of a single pathogenic variant in ATM with an increased risk for 
breast, prostate, and pancreatic cancer.25 One article reports the odds ratio for development of 
pancreatic cancer in individuals with a pathogenic variant in the ATM gene as 4.21 as compared 
to the general population.26 A review of the International Cancer Genome Consortium in 2015 
identified an ATM pathogenic variant in up to 18% of individuals with pancreatic ductal 
adenocarcinoma.27 
Familial pancreatic cancer accounts for a portion of hereditary causes of pancreatic cancer. 
A diagnosis of Familial pancreatic cancer is defined by 2 or more first-degree relatives with 
pancreatic cancer who do not have any other inherited cancer predisposition syndrome or identified 
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germline pathogenic variant associated with an increased risk for PDAC.28 A study conducted by 
researchers at Johns Hopkins concluded that individuals with two affected first-degree relatives 
have a 6.4-fold increased risk for pancreatic cancer. Furthermore, individuals with three or more 
affected first-degree relatives have a 17-fold increased risk for pancreatic cancer. Genome-wide 
association studies (GWAS) continue to search for loci indicative of an increased risk for 
pancreatic cancer in families with familial pancreatic cancer.28 
Table 1: PDAC Risk in Hereditary Cancer Predisposition Genes 
Hereditary Cancer Predisposition 
Syndrome 
 





Familial Atypical Multiple Mole Melanoma CDKN2A 17% 
Lynch syndrome MLH1, MSH2, MSH6, PMS2, 
EPCAM 
3.7% 
Familial Adenomatous Polyposis APC 1-2% 







 ATM increased 
 PALB2 increased 
2.4 Implications of Genetic Testing in Affected Individuals 
While the survival rate for pancreatic cancer is low regardless of the presence or absence 
of a genetic predisposition, advances in medicine have shown the clinical utility of identifying a 
pathogenic variant in a pancreatic cancer predisposition gene in an individual with pancreatic 
cancer. Targeted treatments are available for individuals with pancreatic cancer that harbor 
pathogenic variants in specific genes.  
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Platinum-based chemotherapy has shown clinical benefits in individuals who have a 
pathogenic variant in BRCA1 or BRCA2. Without functional BRCA proteins, cells cannot correctly 
repair DNA in the presence of platinum drugs, which results in cell death.29 This makes platinum-
based chemotherapy more effective in treating cancer in the presence of a BRCA pathogenic 
variant. It is often used in conjunction with other therapeutic agents or prior to surgery.29 
PARP inhibitors are another type of targeted therapy for pancreatic cancer in the presence 
of pathogenic variants in the BRCA pathway. PARP is an acronym for Poly (ADP-ribose) 
polymerase and is a class of enzymes that function in the DNA repair pathway for single-stranded 
breaks. In the presence of a defective DNA repair mechanism caused by a pathogenic variant in 
BRCA, the use of PARP inhibitors can lead to cell death as opposed to proliferation of damaged 
cells.30 One recent phase 3 clinical trial evaluated the use of PARP inhibitors in individuals with 
metastatic pancreatic cancer and a pathogenic variant in BRCA1 or BRCA2.31 This trial showed the 
progression free survival doubled for affected individuals in the group taking PARP inhibitors 
after first-line chemotherapy as compared to the placebo group. 
An additional type of targeted therapy is available for pancreatic tumors that are mismatch 
repair deficient (dMMR) or have microsatellite instability (MSI). Mismatch repair is a vital process 
that occurs within cells to identify and repair mismatched DNA bases that arise during cell 
replication.32 Cancerous tumors which exhibit loss of proteins associated with mismatch repair 
genes are often caused by Lynch syndrome. Pancreatic tumors that present as dMMR/MSI-high 
have a high mutation burden and may respond to an immunotherapy called Pembrolizumab.33 
Pembrolizumab is a programed cell death-1 (PD-1) inhibitor which functions by binding to the 
PD-1 ligand to allow activation of T-cells which recognize and attack cancer cells.34 This is often 
used in the treatment of dMMR/MSI-high colorectal cancer, and has been shown to have a similar 
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response in other types of cancer, including pancreatic adenocarcinoma. There is limited research 
regarding the effectiveness of pembrolizumab in the management of pancreatic cancer due to the 
rarity of dMMR/MSI-high PDAC. However, one study showed normalization of CA19-9 levels 
and regression of disease in several individuals with pancreatic cancer who underwent additional 
treatment with PD-1 immunotherapy.33 
2.5 Implications of Genetic Testing in Unaffected Individuals 
Identification of a pathogenic variant causing a hereditary cancer predisposition can have 
significant implications for unaffected individuals. There is a baseline risk of developing cancer 
that exists for all individuals in the general population, however, identification of a cancer 
predisposition can provide additional information on certain cancer risks and lead to recommended 
surveillance and prevention strategies. This is particularly pertinent for pathogenic variants in 
pancreatic cancer predisposition genes as it is currently not recommended for the general public 
to undergo screening for pancreatic cancer. This recommendation is mostly due to the limitations, 
cost-effectiveness, and efficacy of surveillance. The International Cancer of the Pancreas 
Screening (CAPS) Consortium, American Gastroenterological Association, and National 
Comprehensive Cancer Network (NCCN) recommend pancreatic cancer surveillance for high-risk 
individuals. However, the specific guidelines and recommendations of surveillance vary between 
these organizations, mainly due to differing opinions regarding the limited clinical utility of 
surveillance. The most recent guidelines from CAPS, updated in 2020, categorizes high-risk 
individuals into three groups.6 The first category includes individuals with a pathogenic variant in 
STK11 or CDKN2A, who should be offered surveillance regardless of family history due to the 
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high lifetime-risk for pancreatic cancer. The second category includes individuals with a 
pathogenic variant in BRCA2, BRCA1, PALB2, ATM, MLH1, MSH2, or MSH6, who should be 
offered surveillance when they have at least one affected first-degree relative. The third category 
includes individuals who meet criteria for familial pancreatic cancer (FPC). Unaffected individuals 
from families with FPC would be recommended to consider pancreatic cancer surveillance if they 
have at least one affected first-degree relative.6 
The recommendations for age to begin pancreatic cancer surveillance is dependent on the 
risk category. For individuals who have a known pathogenic variant in STK11 or CDKN2A, 
surveillance is recommended to begin at age 40. For individuals who have a known pathogenic 
variant in BRCA2, ATM, PALB2 BRCA1, MLH1/MSH2/MSH6, surveillance is recommended to 
begin at age 45 or 50, or 10 years before the earliest diagnosis of pancreatic cancer in the family. 
For individuals considered high-risk due to a classification of familial pancreatic cancer, 
surveillance is recommended to begin at 50 or 55, or 10 years before the earliest diagnosis of 
pancreatic cancer in the family.6 
The two imaging tests primarily used for surveillance for pancreatic cancer include 
magnetic resonance imaging of the abdomen (MRI) and endoscopic ultrasound (EUS). Abdominal 
MRI is a type of non-invasive magnetic resonance imaging that produces detailed images of the 
liver, gallbladder, bile ducts, pancreas and pancreatic duct.35 Endoscopic ultrasound is an invasive 
imaging test that involves inserting an endoscope into the mouth and down to the first part of the 
small intestine. The tip of the tube contains an ultrasound probe that is able to capture images of 
the surrounding organs using sound waves.36 Few studies have evaluated the efficacy of the two 
techniques in detecting pancreatic cancer lesions. One meta-analysis found that EUS is a better 
method for detection of small solid lesions, with a sensitivity of 93% for lesions less than 2cm, 
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compared to 67% detection for MRI.37 Conversely, another study found that MRI/MRCP is a better 
method for detection of cystic lesions. In a study of 166 individuals at high-risk for developing 
pancreatic cancer, 23 individuals were found to have a cystic lesion. These lesions were detected 
only by MRI and not EUS.38 Due to the discordance in detection ability, combined MRI and EUS 
remains the recommended modality of screening.6 CAPS currently recommends baseline MRI and 
EUS combined with annual imaging of the pancreas. Many sites alternate MRI and EUS, however, 
there is no consensus as to if and how these modalities should be alternated.6 
In addition to imaging tests, some guidelines recommend measurement of hemoglobin 
A1C (HbA1c) at baseline or the initial evaluation and during routine follow-up surveillance.6 
HbA1c is a measure of glycated hemoglobin. The pancreas plays a vital role in maintenance of 
blood glucose levels in the body. Elevated HbA1c is often a sign of diabetes or prediabetes but can 
additionally indicate the presence of a malignant pancreatic lesion. A prospective cohort study 
evaluated records of 238 individuals seen in a pancreatic cancer multidisciplinary clinic due to a 
recent elevation of hemoglobin-A1c and an identified pancreatic lesion; 196 of these individuals 
were found to have a malignant neoplasm of the pancreas.39  
Additional testing is recommended for individuals suspected of having a pancreatic 
neoplasm based on routine surveillance outcomes. CAPS recommends CA19-9 serum testing and 
CT depending on the outcome of routine surveillance.6 
The primary goal of pancreatic cancer surveillance is to prevent death from pancreatic 
cancer, ideally by identifying a cancer when the tumor is small and confined to the pancreas or an 
advanced precursor lesion (cystic lesion with high-grade dysplasia). A prospective study analyzed 
data from 354 individuals classified as high-risk for PDAC who were enrolled in a Johns Hopkins 
Cancer of the Pancreas Screening cohort studies from 1998 through 2014.40 These individuals 
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underwent routine surveillance with MRI and EUS. At median follow-up of 5.6 years into the 
study, 30 asymptomatic individuals were diagnosed with a clinically significant primary pancreatic 
neoplasm. Additionally, 71% of PDAC’s detected were stage I or stage II indicative of a dramatic 
downstage from the typical detection of PDAC at stage IV.40 
Pathogenic variants in pancreatic cancer predisposition genes that increase the risk of 
pancreatic cancer most often increase the risk of other cancers as well. Identifying a pathogenic 
variant in an unaffected individual may indicate the need for increased surveillance or 
consideration of risk-reducing surgery. In individuals identified to have a pathogenic variant in 
BRCA1 or BRCA2, increased breast surveillance is recommended beginning at age 25, with the 
greatest risk-reduction through a surgical intervention of bilateral mastectomy.41 In individuals 
with a pathogenic variant in one of the mismatch repair genes, increased screening beginning at 
an earlier age is recommended for the detection of colon cancer.42 Identifying a pathogenic variant 
in an individual that increases the risk for pancreatic cancer has the utility of leading to risk 
management options for other types of cancer.  
2.6 Virtual Genetic Counseling 
Genetic counseling is a rapidly growing field, with employment growth around 27% in the 
past two years and predictions for that rate to continue through 2028.43 With the wave of genetic 
discoveries since completion of the Human Genome Project in 2003 and the rapid integration of 
genetic testing into clinical practice, the demand for the knowledge and skillset of genetic 
counselors has greatly increased. In 2017, there were only approximately four-thousand genetic 
counselors in the United States. Models estimate that given the current number of clinical genetic 
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counselors and growth rate for demand, there will be a shortage of around 1,000 genetic counselors 
for the United States population through the year 2026.4 
The shortage of genetic counselors can lead to a variety of challenges, one including wait-
time for an appointment. The average time between requesting an appointment with a genetic 
counselor and having the appointment varies immensely between specialties and geographic 
location. Studies have shown that these wait time can be anywhere from two weeks to three 
months.44 Average wait times for a cancer genetic counseling appointment have been recorded as 
32-43 days in the National Cancer Centre Singapore, 23 days at St. Luke’s Mountain States Tumor 
Institute, and 42-100 days in the Ontario Breast Screening program.44,45 For individuals with 
cancer, long wait times to see a genetic counselor can cause barriers to optimal care for them and 
their families. Genetic testing results have the potential to impact treatment for an individual with 
pancreatic cancer. Genetic testing results of an individual with cancer can also inform the need for 
genetic testing of other family members. Because pancreatic cancer has such a rapid lethality, it is 
especially important to minimize genetic counseling appointment wait times for affected 
individuals. 
This discrepancy in supply and demand of genetic counseling services has created the need 
for utilization of alternative service delivery models. Nearly 50% of genetic counselors use 
alternative service delivery models including telephone, telemedicine, and group counseling.46 
This evaluation was from 2016, prior to the COVID-19 pandemic when clinical genetic counseling 
services were almost exclusively provided via telehealth early in the pandemic.  
Telehealth is the use of a technology-based virtual platform to provide healthcare and 
deliver information. An important reason behind the creation of the telehealth model was to 
provide services for individuals in rural or international locations, individuals that could not leave 
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their homes, and for appointments with rare specialists.47 Currently, the utilization of telehealth 
has significantly increased. There are two main sources of telehealth: video conference and 
telephone. Video conferencing consists of face-to-face interaction with a healthcare provider 
through a HIPAA compliant web-based platform, such as Doxy.me or Thera-LINK. Telephone 
telehealth consists of traditional telephone interaction where you can hear or speak with the 
healthcare provider but not see them. The more novel approaches to virtual healthcare are the use 
of asynchronous telemedicine and pre-recorded video. 
Asynchronous telemedicine occurs when the event of a healthcare provider sharing 
information and the event of the patient or other healthcare provider receiving the information do 
not have to occur simultaneously.48 In other words, a healthcare provider can review imaging, labs, 
medical records and create a care plan that a patient can then view without that healthcare provider 
being present. Asynchronous telemedicine does have restrictions that do not exist for synchronous 
telemedicine. For example, asynchronous telemedicine cannot be used in emergency or adaptive 
situations.48  
The concept of asynchronous telemedicine has been applied to pre-recorded videos for 
health education. The use of these videos is comparable to the concept of a flipped classroom 
model. In a flipped classroom model, students gain foundational knowledge by viewing 
PowerPoint presentations, reading book chapters, or watching pre-recorded lectures. The students 
then use that foundational knowledge to engage in assignments and in-class discussion.49 This 
same concept applies to the use of pre-recorded videos, in which patients can view a video 
presenting relevant health education information and then follow up with a healthcare provider 
with any questions. While the interactions between patients and health care providers are 
significantly different from that of students and professors, the similarities in this situation reflect 
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the concept of providing foundational knowledge via video and then following up with an expert. 
One study has been done to evaluate the cross-bridge of a flipped classroom model as a means of 
presenting medical information.50  
This study took place in Pakistan and included a pre-recorded video which educated 
medical students about physician-patient communication skills. An assessment was done to 
evaluate the communication skills each physician used to present certain clinical counseling topics 
to patients, before and after watching the educational video. A statistical difference in scoring of 
communication skills suggests that video education was an effective teaching method.50  
The use of pre-recorded video in genetic counseling is beginning to find footing in the field 
as a new way to combat the shortage of genetic counseling services. There are many studies that 
assess the use of interactive video health education, but minimal published research on the topic 
of pre-recorded video health education and even less on the use of the model in genetic counseling. 
One study trialed the use of animated videos in a pediatric emergency department waiting room. 
These videos provided tips for managing common illnesses at home and alternative ways of 
seeking medical advice that did not involve the emergency department. Twenty-two of twenty-
seven parents who viewed the video reported that the video would influence their behavior the 
next time their child was sick.51 
Two studies have evaluated the use of video education in genetic counseling. One study 
was the MAGENTA trial, which evaluated the utility of video education regarding genetic testing 
with and without pre- and post- test genetic counseling.52 The goal of this study was to make 
genetic testing more widely available for individuals at risk for hereditary breast and ovarian 
cancer given a family history of the condition or personal history of breast cancer. The primary 
outcome of the study was evaluation of cancer risk distress in patients after receiving education 
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about genetics and cancer. Results showed that the video education was successful in reducing 
patient distress.52 Another study evaluated the use of a genetic counseling educational video for 
women with ovarian, fallopian, and peritoneal carcinomas. The purpose of this study was to 
evaluate the proportion of women who elected to undergo genetic testing after the video education 
compared to those who were offered an in-person appointment with a genetic counselor.53 The 
results of this study showed that 29% of individuals who were offered an appointment with a 
genetic counselor underwent genetic testing and 55% of individuals who had video education 
underwent genetic testing.53 The reasoning behind this difference requires further evaluation and 
is not resistant to the influence of potential external factors such as declining of counseling 
services, insurance coverage, and language limitations. However, the findings of this study offer 
evidence of the utility of video education in providing genetic information.  
2.7 Influence of Health Literacy in Genetic Counseling 
Health literacy is defined as “the degree to which individuals have the capacity to obtain, 
process, and understand basic health information and services.”54 More than one-third or 80 
million adults in the United States have limited health literacy.54 Limited health literacy makes it 
difficult for individuals to understand health information and make informed decisions. This 
subsequently results in a number of burdens for the healthcare system, including increased health-
care costs, limited patient knowledge of their own diseases and treatments, fewer self-management 
skills and ability to care for chronic conditions, poor compliance, increased hospitalizations, and 
reduced access to correct health care services.55  
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Health literacy in the context of genetic counseling becomes particularly complicated. 
Genetic counseling is by nature a non-directive type of health care interaction. Genetic information 
is presented to patients, typically with the caveat of patients then choosing their next steps, e.g., 
the decision to pursue genetic testing. This focus on patient autonomy makes health literacy even 
more paramount to ensure that patients have a sufficient level of comprehension of the information 
being presented in order to make an informed decision. One study assessed genetic literacy through 
administration of a questionnaire which addressed basic concepts of genetics to over 5,000 
participants. The average correct score on the questionnaire was 65.5%, which represents 
significant limitations in genetic literacy in the population.56 
There are many reasons for which individuals decline genetic testing in the presence of a 
personal cancer diagnosis. Several studies have evaluated the factors that play a role in decision 
making for genetic testing. One study looked at individuals who faced the opportunity to undergo 
genetic testing for hereditary colorectal cancer syndromes. The most common reasons for people 
to decline genetic testing after receiving education about the testing options were: lack of 
understanding about the purpose and benefits of genetic testing, belief that the test result wouldn’t 
alter their care, and insurance concerns.57 Another study analyzed individuals who were eligible 
for BRCA1/BRCA2 testing, and found that 44% of individuals pursued genetic testing and 56% 
declined testing. Interviews with the study participants revealed the most common reason they 
pursued genetic testing was due to the desire to better manage their own cancer risk and the cancer 
risk for close relatives. Conversely, the most common reasons participants declined testing was 
the perceived irrelevance of the result on their health management and concerns about insurance 
discrimination.58  
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Many connections have been made which demonstrate the influence of health literacy on 
the decision-making process to pursue or decline genetic testing. One study found that individuals 
with limited health literacy were significantly less likely than those with adequate health literacy 
to perceive family history as very important in the decision to pursue genetic testing.59 Another 
study analyzed the connection between health literacy and cancer risk perception through 
discussion of the recurrence risk for breast cancer. Results concluded that individuals with lower 
health literacy gave more variable interpretations of presented risks and had a reduced ability to 
associate risk with recommendations for chemotherapy.60 
These findings indicate that an individual’s level of health literacy influences their ability 
to understand both personal and family cancer risk information, and subsequently their ability to 
make an informed decision about pursuing genetic testing. In other words, if an individual with 
limited health literacy has a lower proclivity to understand their personal risk for cancer occurrence 
when they have a pathogenic variant, then they may be less likely to pursue genetic testing despite 
the recommendations about subsequent surveillance.  
A study through the National Institute of Aging analyzed the ability of patients to correctly 
recall health information being orally presented to them by a healthcare provider, in relation to the 
patient’s baseline health literacy.61 Results of the study showed significant reduction in patient 
recall of information in individuals with limited health literacy. The outcome demonstrated patient 
recall mean scores of 2.5 in the low literacy group vs 4.6 in the adequate literacy group with a 
significant p-value of less than 0.001. Additionally, individuals with adequate literacy had a recall 
rate as low as 31% for specific items. This suggests a lack of understanding of health care 
information even in individuals with adequate health literacy.  
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Health literacy is additionally an important factor in influencing the incidence of cancer. 
While many types and diagnoses of cancer are unpreventable, we do know there are modifiable 
risk factors that increase an individual’s chance of developing cancer. An analysis of the 2013 U.S. 
Health Information National Trends Survey evaluated the correlation between health literacy and 
cancer prevention beliefs.62 Individuals with low health literacy were significantly more likely to 
endorse the notion that cancer prevention is not possible than individuals with higher health 
literacy. This is reflective of the association of limited health literacy with comprehension of 
proper health maintenance recommendations.  
Given the significant impact of health literacy on decision-making and behaviors, certain 
tools have been developed to gauge patient health literacy in the field of genetics. The Rapid 
Estimate of Adult Literacy in Genetics (REAL-G) questionnaire was developed as a tool for 
determination of genetic literacy.63 The short form is comprised of 8 words commonly used in 
cancer and/or prenatal genetic counseling. Participants are asked to read the words aloud. 
Individuals who cannot pronounce 3 or more words fall into the category of low literacy, equating 
to a reading level at or below 6th grade. Analysis of the utility of this tool revealed a sensitivity of 
89.3% and a specificity of 80.8% to identify individuals with low literacy.63 
2.8 Patient Satisfaction of Virtual Health Education 
The National Society of Genetic Counselors (NSGC) has long focused on patient-centered 
healthcare. The statement of Diversity, Equity, and Inclusion states “The skills of genetic 
counselors are exactly those needed to promote a diverse and inclusive organization: empathy, 
tailored communication, problem solving, advocacy, and the ability to support people of all 
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backgrounds through important moments in their lives.” With the movement of genetic counseling 
into mainstream healthcare comes the challenge of ensuring patient satisfaction with genetic 
counseling services. Few studies and data analyses have been performed to sift through the gaps 
in communication that occurs when presenting a particularly complex field of medical science 
through a non-interactive video. 
Disconnect in communication between patient and provider is a particularly salient issue 
in the growth of telemedicine and online education tools. This is because any problems with 
comfort, communication, and satisfaction have the potential to become exacerbated when moved 
to a virtual platform. While many studies have been done to evaluate the efficiency and 
functionality of health care provided via a virtual platform and patient satisfaction of telehealth 
services, research regarding patient satisfaction of video education of genetic counseling 
information is significantly lacking.64-66 
A pilot study was performed over the period of four years at two hospitals in California to 
evaluate patient review of communication and satisfaction regarding an in-person genetic 
counseling appointment.67 One hundred seventy genetic counseling sessions were observed to 
assess the mismatch of patient information needs and information provided by counselors. The 
main components of the session that yielded ineffective communication were (1) too much 
information; (2) complex terminology and conceptually difficult presentation of information; (3) 
information perceived as not relevant by the patient; (4) unintentional inhibition of patient 
engagement and question asking; (5) vague discussions of screening and prevention 
recommendations. Mismatch information issues that exist with in-person genetic counseling may 
be even more difficult to address in interactions that eliminate active engagement between genetic 
counselor and patient.   
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A meta-analysis looked at multiple studies that evaluated patient satisfaction with 
telemedicine. Telemedicine was shown to have various impacts on quality of care in comparison 
to in-person counseling. Improvements in telemedicine revolved around convenience. Reductions 
in patient satisfaction of telemedicine included absence of body language communication, back 
and forth discussion, and delivery of handouts.68 Another pilot study through a stroke center in 
Houston analyzed the use of a pre-recorded video to provide health education to individuals who 
had undergone a stroke.69 A 5-minute video regarding stroke education was presented to 
participants upon hospital discharge along with a 10-item questionnaire. Prior to watching the 
video, 49.5% of participants were “very satisfied” with the stroke education they had received 
while in the hospital. There was a significant increase in satisfaction after watching the video of 
74.2% of participants saying they were “very satisfied.”  
Results of these studies represent the need for additional analysis of patient satisfaction of 
telehealth genetic counseling. This analysis would focus on aspects unique to pre-recorded video 
education as opposed to live telemedicine sessions. Future directions for studies would combine 







Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal forms of cancer. In 
recent years, PDAC has been responsible for over 400,000 deaths globally each year. While the 
United States has made many advancements in medicine and treatment, PDAC remains the third 
most common cause of cancer-related deaths in the United States, with a 5-year survival rate of 
9%.1  
Extensive research has identified many factors that cause an increased risk for PDAC. 
These factors include modifiable risks such as tobacco use, obesity, and environmental exposures 
and non-modifiable risk factors such as age, gender, race, blood group, family history, and genetic 
predisposition.9-11,14 Approximately 10% of individuals with PDAC harbor a germline pathogenic 
variant in a gene associated with increased risk for cancer.1 An increased risk for PDAC has been 
associated with many hereditary cancer predisposition syndromes that have well-defined risks for 
various types of cancer and guidelines for risk management. These syndromes include Hereditary 
Breast and Ovarian Cancer syndrome (HBOC), Lynch Syndrome, Peutz-Jeghers syndrome, 
Familial Atypical Multiple Mole Melanoma (FAMMM), Familial Adenomatous Polyposis (FAP), 
and Li-Fraumeni syndrome.15 New research continues to identify additional genes that are 
associated with an increased risk for PDAC.16,23,25  
Current guidelines recommend a genetics evaluation and germline genetic testing for a 
hereditary cancer predisposition for all individuals diagnosed with PDAC.3,6 Determining the 
germline status for individuals with PDAC can inform the cancer risks for family members and 
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potentially impact treatment of the affected individual. Pathogenic variants in certain genes are 
more likely to respond to specific medications that can further aid in treatment of cancer.29,30,34 
The International Cancer of the Pancreas (CAPS) Consortium has specific recommendations for 
PDAC surveillance in high-risk individuals.6 High-risk individuals include those identified to have 
a genetic predisposition to PDAC. Studies have shown that routine surveillance can identify PDAC 
at earlier, more treatable stages.40 
Genetic testing for hereditary cancer predisposition syndromes is often facilitated by 
genetic counselors. However, the current genetic counseling workforce is not meeting the demand 
for their services nationwide, which limits the completion of this testing.4 While germline genetic 
information can be theoretically tested at any time due to its fixed nature, individuals with PDAC 
often do not have time. The poor average survival rates from this cancer means that individuals 
may die before obtaining access to genetic services. Additionally, genetic counselors are mainly 
located in high-population urban settings, resulting in limited access to genetic services.47 
Limitations such as cancer lethality and limited access to genetic counseling services represent the 
need for exploration of alternative service delivery models.  
Video education has become a growing alternative to traditional delivery of health services. 
In this model, a pre-recorded video of pertinent health information is presented to patients, with 
the opportunity to follow-up with a health care provider if needed.48 This information delivery 
method had been evaluated in two genetic studies as a means to make genetic testing more widely 
available to individuals.52,53 One of these studies resulted in a 55% uptake of genetic testing for 
individuals who received video education.53 However, the use of video education has the potential 
to exacerbate the communication issues and emotional burden that comes from learning complex 
and potentially life-changing genetic information.67 
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The purpose of this study was to evaluate the effectiveness and patient satisfaction of video 
education discussing the genetics of PDAC. Most studies of web-based healthcare delivery assess 
the functionality of live telehealth consultations. There is minimal published information regarding 
the use of pre-recorded videos in the field of genetics, and even less information regarding patient 
satisfaction of such videos as an educational tool. This study aims to guide future directions for 
the delivery of genetic information about PDAC in a manner that addresses some of the challenges 
associated with access within the field of genetic counseling.  
3.2 Methods 
3.2.1 Participants 
IRB approval for this study was granted on November 6, 2019 and the approval letter can 
be found in Appendix A.5. The University of Pittsburgh Medical Center (UPMC) created a 
Multidisciplinary Clinic (MDC) for patients newly diagnosed with PDAC. The clinic is designed 
with the goal of having all necessary specialists meet with the patient in one appointment. 
Specialists include medical oncologist, surgical oncologist, pain management, dietician, clinical 
trials coordinators, clinical labs coordinators, and genetic counselors. A conference is held prior 
to each clinic in which all the specialists review imaging, labs, pathology reports, and medical 
history in order to determine the treatment plan for each patient.  
The clinic is held one day a week and takes place in two locations. The morning clinic is 
held at Hillman Cancer Center and the afternoon clinic is held at Presbyterian Hospital. The clinic 
structure and specialists available are the same at both clinics. The two study groups were assigned 
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based on clinic location. Patients seen at Hillman Cancer Center were assigned to the traditional 
genetic counseling group and patients seen at Presbyterian Hospital were assigned to the video 
education group.   
3.2.2 Eligibility Criteria 
The inclusion criteria for this study are individuals with histologically confirmed pancreatic 
ductal adenocarcinoma who were being seen in the MDC. Patients were eligible regardless of age, 
sex, stage of disease, and personal or family history of cancer. The exclusion criteria for this study 
are individuals who had an identified pathogenic variant in a cancer predisposition gene, 
individuals who previously underwent multi-gene germline panel testing that included pancreatic 
cancer susceptibility genes, and individuals who could not provide informed consent to participate 
in the research study.  
3.2.3 Recruitment 
In both clinics, potential participants were invited to participate during their appointment 
in their exam room. It was explained to patients that they would be either meeting with a genetic 
counselor or watching an educational video about genetics, dependent on their clinic site. Details 
of the study, including all research related activities, were reviewed with the patients. All questions 
regarding participation were answered and patients who agreed to participate in the study provided 
informed consent. Subsequent genetic counseling or video education and questionnaire 
administration also took place in the patient’s exam room.  
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3.2.4 Data Collection Tools 
In this research study, three questionnaires were used to collect data for evaluation of 
endpoints. Copies of all questionnaires are located in Appendix A. The REAL-G instrument is a 
validated questionnaire that was used to assess participants’ baseline genetic literacy. The Genetic 
Knowledge Questionnaire was designed for this study to assess participants’ pancreatic cancer 
genetic knowledge. The Patient Satisfaction survey was designed for this study to assess 
participants’ satisfaction of their designated delivery method of genetics education.  
The REAL-G was completed verbally by the patient. The Genetics Knowledge 
Questionnaire was administered orally by the research investigator reading the prompts out loud. 
The Patient Satisfaction Survey was completed by the patient in writing.  
3.2.4.1 REAL-G Short Form 
The Rapid Estimate of Adult Literacy in Genetics (REAL-G) is a validated questionnaire 
that was developed based on the Rapid Estimate of Adult Literacy in Medicine (REALM) as a 
means to achieve an understanding of individuals’ baseline level of health literacy.63 The REAL-
G consists of 63 words frequently discussed in prenatal and/or cancer genetic counseling sessions. 
The REAL-G short form was adapted from the original questionnaire and consists of 8 words 
commonly discussed in genetic counseling. The REAL-G short form was used in this study to 
measure each participant’s familiarity with genetic terms prior to receiving any genetics education.  
After completing the consent process, participants were given the REAL-G short form and 
asked to read the words out loud. They were instructed to pronounce all words to the best of their 
abilities and told that they could skip over any word they could not pronounce. The investigator 
administering the instrument also had a copy of the questionnaire in order to track the participant’s 
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responses. The words in the REAL-G short form are “genetic,” “sporadic,” “mutation,” 
“variation,” “chromosome,” “hereditary,” “abnormality,” and “susceptibility”.  
Words that the participant pronounced correctly were marked with a “+” on the 
investigator’s form. Words that the participant pronounced incorrectly or skipped were marked 
with a “-“ on the investigator’s form. A total of 3 or more missed or skipped words equates to a 6th 
grade or below reading level.63 
3.2.4.2 Genetic Knowledge Questionnaire 
The Genetics Knowledge Questionnaire was constructed specifically for this study. No 
published questionnaires could be identified in the literature that include all the necessary aspects 
to accomplish the aims of this study. A genetics questionnaire for adolescents and young adults 
with congestive heart failure was used as framework for the creation of this questionnaire.70 The 
Genetics Knowledge Questionnaire was designed to evaluate patient knowledge of genetic 
information about PDAC that was addressed during their appointment at the MDC.  
The questionnaire was created by the investigators, including two genetic counselors who 
specialize in gastrointestinal cancer genetics. The questionnaire consists of seven true/false 
statements. Each statement was assigned one point. Individuals who answered the statement 
correctly received one point and individuals who did not answer the statement correctly received 
zero points. Therefore, the maximum number of points someone could receive was seven. The 
statements each contain information about the genetics of pancreatic cancer that was presented to 
the participant either by the genetic counselor or through the educational video.  
The questionnaire was intended to be administered verbally by a study investigator at two 
timepoints. The first timepoint was in-person in the MDC immediately following genetic 
education. The second timepoint occurred over the phone at a time interval detailed in the study 
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protocol. During both timepoints, the investigator read each statement out loud and prompted the 
participant to classify each statement as true or false based on the genetics education they received. 
The investigator marked a “√” in the appropriate column on their form. The number of questions 
that the participant correctly designated as true or false was recorded.  
3.2.4.3   Patient Satisfaction Questionnaire 
The Patient Satisfaction Questionnaire was constructed specifically for this research study. 
There are no published questionnaires in the literature that specifically address patient satisfaction 
regarding delivery of genetics education using a pre-recorded video. Two satisfaction 
questionnaires for traditional genetic counseling sessions were used as the platform for creation of 
this questionnaire.71,72 The Patient Satisfaction Questionnaire was designed to evaluate patient 
satisfaction of their designated method of delivery of genetic information about PDAC during their 
appointment including assessment of  clarity, relevance, directiveness, reliability, personalization, 
trustworthiness, and ability to prepare individuals to make a decision about genetic testing. 
The questionnaire was created by the investigators and the advisory team for this research 
study. The questionnaire consists of seven statements to which the study participants respond using 
a Likert scale. The statements contain information discussing evaluation and impression of the 
mode of delivery of genetic information. The Likert scale includes the options “strongly disagree,” 
“disagree,” “neutral,” “agree,” and “strongly agree.” Each statement in the Likert scale was 
assigned a certain number of points: 1- strongly disagree, 2 – disagree, 3 -neutral, 4 – agree, 5 – 
strongly agree. Three statements were intentionally made negative statements to ensure that 
individuals were reading and comprehending the questionnaire, and to eliminate response bias. 
The three negative statements were reverse scored in data analysis of satisfaction responses. A 
higher score equates to a more positive reaction to the statement.  
 32 
The questionnaire was administered at one timepoint by the investigator during the MDC 
clinic immediately following genetic education. The participant was given a copy of the 
questionnaire and asked to read it and complete it themselves by marking their responses with a 
“√” in each appropriate column.  
3.2.5 Study Protocol 
The research team for this study consisted of a genetic counseling student who facilitated 
the enrollment process and administration of questionnaires, two cancer genetic counselors, 
several surgical oncologists and medical oncologists, a gastroenterologist, and additional research 
coordinators. The study consisted of two parts. Part one was a continuation of the pilot study which 
assessed participant genetic knowledge. Part two was a novel addition to the study which assessed 
participant satisfaction. 
Recruitment of patients into the research study occurred in the MDC. Patients who met the 
inclusion criteria were approached during clinic, provided information about participation in the 
study and given the opportunity to ask questions. Patients who declined participation in the study 
were still offered the opportunity to receive genetics education and pursue genetic testing during 
MDC or through referral to the Hereditary GI Tumor program. Patients who agreed to participate 
in the study provided informed consent by reviewing and signing the consent form. 
The consent process was followed by the activities of timepoint 1. The REAL-G 
questionnaire was administered, and responses recorded. In the traditional genetic counseling 
group, the genetic counselor then met with the patient and provided genetic counseling. The results 
of the REAL-G were not disclosed to the genetic counselor prior to their discussion with the patient 
in order to prevent bias in their counseling style.  The traditional genetic counseling session was 
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an abbreviated version of a standard cancer genetic counseling appointment to accommodate the 
nature of a multidisciplinary clinic. This consisted of collection of a pedigree, education about 
hereditary pancreatic cancer, discussion of the risks, benefits, and result outcomes of genetic 
testing, and completion of paperwork if appropriate. This also included the opportunity for patients 
to ask questions of the genetic counselor. Time spent with the genetic counselor was variable, but 
typically lasted approximately 20 minutes.  
In the video education group, a 5-minute video was played for the patient to provide 
genetics education after the completion of the REAL-G questionnaire. The video was developed 
by licensed and certified genetic counselors who specialize in gastrointestinal cancer genetics. This 
video was a narrated PowerPoint slide deck presented on a tablet. The video included a brief 
education about hereditary pancreatic cancer, and discussion of the risks, benefits, and result 
outcomes of genetic testing. The video directed the participants to bring any questions they may 
have to the providers at the MDC. A pedigree was not collected for individuals in the video group.  
Immediately following the genetics session in both groups, the participants were 
administered the Genetics Knowledge Questionnaire orally by the investigator and responses were 
recorded. The participants were then given the Patient Satisfaction Questionnaire to complete and 
the instrument was retrieved and kept by the investigator. Participants were instructed to complete 
the questionnaires on their own without assistance from any individuals that may have 
accompanied them to the appointment.  
Participants who elected to undergo genetic testing were offered testing through Invitae’s 
Detect study, which waives the price of the genetic test for individuals with PDAC. Study 
participants were aware that testing was being offered at no cost.  For the Detect study, participants 
who underwent genetic testing prior to April 2020 received a panel containing 84 genes and 
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participants enrolled after April 2020 received a panel containing 49 genes associated with 
increased risk for pancreatic cancer and other cancers. A complete list of analyzed genes can be 
found in Appendix C. Genetic testing was completed via a blood sample upon conclusion of the 
MDC appointment. If the genetic testing was not able to be completed on the day of the 
appointment, participants were sent a saliva kit to mail in their specimen for genetic testing. 
Timepoint 2 occurred four weeks after the participants’ appointment at the MDC. 
Participants were contacted via telephone. At this time, participants were reminded of their 
participation in the study and were asked if they would answer follow-up questions for data 
collection. If the participant agreed, then the Genetics Knowledge Questionnaire was administered. 
The investigator re-explained the instructions of the questionnaire and then read the statements out 
loud and recorded the responses. Participants were then thanked for their participation in the 
research study and were told their participation was complete. If participants did not agree to 
answer follow-up questions, then they were told their participation was complete.  
Genetic testing results were returned to the participant when they became available. 
Participants in the traditional genetic counseling group received their results over the phone from 
the genetic counselor they spoke with at the time of their MDC appointment. Participants in the 
video education group received results from a member of the MDC care team who was trained by 
the genetic counselors to return results. Any participant who was in the video education group and 
was found to have a pathogenic variant was referred to meet with a genetic counselor in the 





Figure 1: Protocol Workflow 
 
3.2.6 Data Analysis 
The software systems Microsoft Excel and STATA (StataCorp version 15) were used for 
all data analyses. Non-parametric tests were used given the lack of normal distribution and small 
sample sizes. A Fisher’s Exact Test was used for comparisons of sex and literacy with education 
group. A Wilcoxon rank-sum (Mann-Whitney) test was used for comparisons of age, knowledge 
score, and satisfaction score between the two groups, and a comparison of genetic literacy group 
with knowledge score. A Wilcoxon signed-rank test was used to compare knowledge scores 
between timepoints. A Spearman correlation test was used to compare interval between timepoints 
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and change in knowledge score. P values were considered significant when less than 0.05. Output 
from STATA can be found in Appendix B. 
3.3 Results 
Recruitment of participants for part one of the study began January 8th, 2020, and ended 
December 9th, 2020. Recruitment was temporarily ceased for three months due to the COVID-19 
pandemic. A total of 64 participants consented to be in part one of the study, which evaluated 
patient knowledge. Thirty-two participants were enrolled in each group; video education group 
and traditional genetic counseling group. Each of these participants completed the REAL-G 
questionnaire and knowledge questionnaire at timepoint one. Of the 64 participants, 50 participants 
completed timepoint two. Fourteen participants were not able to complete timepoint two for the 
following reasons: two died before reaching timepoint two, six were lost-to-follow-up, and six 
elected not pursue genetic testing and were therefore not eligible for timepoint two.  
Recruitment of participants for part two of the study began September 16th, 2020, and 
ended December 9th, 2020. A total of 25 patients were enrolled in the second portion of the study, 
which evaluated patient satisfaction. Each of these participants completed the patient satisfaction 
questionnaire at timepoint one. Eleven participants were enrolled into the traditional genetic 
counseling group and fourteen participants were enrolled into the video education group.  
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3.3.1 Demographics 
Of the 64 participants, the overall mean age was 67.9 (± 9.95) with a range of 41 to 87 
years. The mean age of the traditional genetic counseling group was 69.5 (± 8.66) with a range of 
52 to 87 years. The mean age of the video education group was 66.2 (± 10.85) with a range of 41 
to 84 years. There was no significant difference between age for groups (p-value = 0.3400). Of the 
total participants, 62.5% (40) were male and 37.5% (24) were female. In the traditional education 
group, 53.1% (17) were male and 46.9% (15) were female. In the video education group, 71.9% 
(23) were male and 28.1% (9) were female. There was no significant difference between sex for 
groups (p-value = 0.196) (Table 2). 
 
Table 2: Participant Demographics 
Group Traditional Education Video Education Total 
 n = 32 n = 32 n = 64 
Age (years)    
Mean 69.5 66.2 67.9 
Range 87-52 = 35 years 84-41 = 43 years 87-41 = 46 years 
Sex 
proportion (n) 
   
Male 53.1% (17) 71.9% (23) 62.5% (40) 
Female 46.9% (15) 28.1% (9) 37.5% (24) 
 
3.3.2 Baseline Genetic Literacy 
Baseline genetic literacy was determined from administration of the REAL-G 
questionnaire. Of the 64 total participants, 15.6% (10) were identified to have low literacy 95% CI 
[0.067-0.245]. There were 12.5% (4) individuals with low literacy in the traditional education 
 38 
group 95% CI [0.044-0.206] and 18.8% (6) individuals with low literacy in the video education 
group 95% CI [0.092-0.284]. There was no significant difference between literacy for education 
groups (p-value = 0.732) (Table 3). 
 
Table 3: Genetic Literacy 
Literacy Group Traditional Education Video Education Total 
 n=32 n=32 n=64 
6th Grade or Below 12.5% (4) 18.8% (6) 15.6% (10) 
Above 6th Grade 87.5% (28) 81.3% (26) 84.4% (54) 
 
3.3.3 Genetic Knowledge in Comparison to Literacy and Education Group 
Genetic knowledge was determined from the Genetic Knowledge Questionnaire. The mean 
number of questions answered correctly across all groups and literacy levels following genetics 
education was 5.7 (± 0.95) out of possible 7. The mean knowledge score for individuals determined 
to have low literacy was 5.3 (± 1.2) and those determined to have adequate literacy is 5.8 (± 0.87). 
There was no statistical difference between literacy level and knowledge score (p-value =  0.2284) 
(Table 4). 
The mean knowledge score for individuals with low literacy in the traditional education 
group was 5.0 (± 1.41) and the mean score for those with low literacy in the video education group 
was 5.5 (± 0.96). The mean knowledge score for individuals with adequate literacy was 5.8 in both 






Table 4: Mean Knowledge Score by Literacy Level and Education Group 
Literacy Group Traditional Education Video Education Overall 
6th Grade or Below 5.0 5.5 5.3 
Above 6th Grade 5.8 5.8 5.8 
Total Average  5.4 5.7  
 *Mean score on the knowledge questionnaire out of 7 possible points 
3.3.4 Genetic Knowledge Across Timepoints 
The study protocol indicated four weeks between timepoint 1 and timepoint 2 to administer 
the knowledge questionnaire. However, for logistical reasons this interval was not always four 
weeks. The mean interval between timepoints was 32 days (± 8.79). A correlation test was 
performed to determine if length of interval time influenced change in knowledge score between 
timepoint 1 and timepoint 2. There was no statistical correlation between interval time and change 
in knowledge score (p-value = 0.4211). 
Sixty-four participants were enrolled in part one of this study and completed the genetic 
knowledge questionnaire at timepoint 1. Fifty participants completed the genetic knowledge 
questionnaire at timepoint 2 and were analyzed across both timepoints (Table 5). The mean 
knowledge score for all participants in both groups at timepoint 1 and timepoint 2 was 5.7 (± 0.95) 
and 5.3 (± 1.11), respectively. There was no statistical difference in overall knowledge score 
between timepoint 1 and timepoint 2 (p-value = 0.1359). 
The mean knowledge score for timepoint 1 and timepoint 2 in the traditional education 
group was 5.7 (± 0.99) and 5.3 (±1.10), respectively. This represented an average reduction in 
knowledge score for the second timepoint of 0.25 (± 1.43), which was not statistically significant 
(p-value = 0.4096). Thirteen participants had a decrease in knowledge score at timepoint 2 as 
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compared to timepoint 1, nine participants had an increase in knowledge score at timepoint 2, and 
six participants had the same knowledge score at both timepoints.  
The mean knowledge score for timepoint 1 and timepoint 2 in the video education group 
was 5.8 (± 0.90) and 5.2 (± 1.13), respectively. This represented an average reduction in knowledge 
score for the second timepoint of 0.45 (± 1.27), which was not statistically significant (p-value = 
0.1573). Nine participants had a decrease in knowledge score at timepoint 2 as compared to 
timepoint 1, six participants had an increase in knowledge score at timepoint 2, and seven 
participants had the same knowledge score at both timepoints.  
 
Table 5: Mean Knowledge Score by Timepoint 
 Timepoint 1 Timepoint 2 Average Change in 
Knowledge 
 n=64 n=50  
Traditional 
Education 
5.7 5.3 - 0.25 (± 1.43) 
Video Education 5.8 5.2 - 0.45 (± 1.27) 
 
3.3.5 Satisfaction in Comparison to Education Group 
Participant satisfaction of their education method was measured through administration of 
the satisfaction questionnaire at timepoint 1. Comparison of satisfaction scores and corresponding 
p values can be found in Table 6. The mean satisfaction score for statement one in the traditional 
education group and video education group was 4.1 (± 1.00) and 3.9 (± 0.80), respectively, which 
was not statistically significant (p-value = 0.5206). This was a negative statement which was 
reverse scored for the data analysis. The mean satisfaction score for statement two in the traditional 
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education group and video education group was 3.7 (± 1.05) and 3.9 (± 0.70), respectively, which 
was not statistically significant (p-value= 0.8577). The mean satisfaction score for statement three 
in the traditional education group and video education group was 3.8 (± 1.11) and 4.3 (± 0.45), 
respectively, which was not statistically significant (p-value= 0.3159). 
The mean satisfaction score for statement four in the traditional education group and video 
education group was 4.4 (± 0.77) and 4.1 (± 0.96), respectively, which was not statistically 
significant (p-value = 0.4162). This was a negative statement which was reverse scored for the 
data analysis. The mean satisfaction score for statement five in the traditional education group and 
video education group was 3.8 (± 1.19) and 4.4 (± 0.48), respectively, which was not statistically 
significant (p-value= 0.3279). 
The mean satisfaction score for statement six in the traditional education group and video 
education group was 3.8 (± 0.94) and 2.9 (± 0.88), respectively, which was not statistically 
significant (p-value = 0.0537). This was a negative statement which was reverse scored for the 
data analysis. The mean satisfaction score for statement seven in the traditional education group 
and video education group was 4.0 (± 0.95) and 4.1 (± 0.52), respectively, which was not 
statistically significant (p-value= 0.9027). 
The total satisfaction score (out of possible 35 points) was calculated for each participant 
and compared between traditional and video education groups. The mean total satisfaction score 
for the traditional education group was 28.9 (± 3.29) and for the video group 26.6 (± 3.81), which 






Table 6: Satisfaction Score by Education Group 
Statement Traditional 
Education 
Video Education P-value  
The information presented about 
genetic testing was difficult to 
follow 
*4.1 *3.9 0.5206 
The information presented about 
genetic testing felt relevant to my 
diagnosis 
3.7 3.9 0.8577 
The information provided 
explained the purpose of genetic 
testing for a person with 
pancreatic cancer 
3.8 4.3 0.3159 
Based on the information 
presented (in the video/by the 
genetic counselor), I do not feel 
comfortable making a decision 
about getting genetic testing 
*4.4 *4.1 0.4162 
I trust that the information about 
genetic testing presented (in the 
video/by the genetic counselor) is 
accurate 
3.8 4.4 0.3279 
I wish I had more of an 
opportunity to ask questions 
about genetic testing 
*3.8 *2.9 0.0537 
I would recommend (the 
video/speaking with a  genetic 
counselor) to other people with 
pancreatic cancer as a way to 
learn about genetic testing 
4.0 4.1 0.9027 
Total Satisfaction Score 
 
28.9 26.6 0.1048 
*Reverse scored 
3.3.6 Genetic Testing Results 
Of the sixty-four participants who were enrolled in part one of this study, fifty-seven 
elected to undergo genetic testing. Three of the individuals who elected to undergo genetic testing 
never had their sample collected. For these three individuals, genetic testing was not able to be 
completed on the day of the appointment so alternative options were discussed to complete the 
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genetic testing at a later time. None of these three individuals had results returned by the 
completion of the data analysis. Four individuals underwent genetic testing, but the results were 
not made available to the study team. Of the 50 participants whose results were returned by the 
completion of the study, 9 were identified to have a pathogenic variant, 17 were identified to have 
at least one variant of uncertain significance (VUS), and 24 had negative results. This means that 
18% of participants in this study with pancreatic ductal adenocarcinoma were identified to have a 
pathogenic variant in a hereditary cancer predisposition gene 95% CI [0.07-0.29]. Four of the 
participants with a pathogenic variant were in the traditional education group and five were in the 
video education group.  
The pathogenic variants were identified in ATM, APC, BLM (heterozygous), BRCA2, 
CHEK2 (x2) MUTYH (x2, heterozygous) and TP53 (mosaic). The variants of uncertain 
significance were identified in APC, AXIN2, BRCA1, CDKN2A, CEBPA, MET, MSH2, MSH3, 
NF2, PDGFRA, PMS2, POLE, RAD50, RECQL4, SDHA, and TSC2.  
3.4 Discussion 
In 2018, the American Society of Clinical Oncology updated their guidelines to 
recommend universal genetic testing for a hereditary predisposition to cancer in all individuals 
with pancreatic ductal adenocarcinoma (PDAC).2 The National Comprehensive Cancer Network 
shortly followed suit and updated their clinical criteria for genetic testing to include anyone with 
a diagnosis of PDAC.3 This prompted the demand for oncology genetic counselors to 
accommodate these new testing recommendations. Genetic counseling continues to be a 
developing field, with a shortage of genetic counselors per individual in need of genetic services 
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in the United States estimated to persist through the year 2026.4 This projection was based off U.S. 
and U.K. data evaluating supply and demand of genetic counseling services, which concluded a 
recommendation of one full-time equivalent genetic counselor per 75,000 people in the United 
States.43 This discrepancy in supply and demand of genetic counselors prompts the need for 
alternative methods of delivering genetic counseling services. University of Pittsburgh Medical 
Center (UPMC) created an educational video about genetic testing for pancreatic cancer in effort 
to increase access to germline genetic testing.  By using an educational video to explain genetic 
testing for pancreatic cancer, genetic counselors can focus their services on individuals identified 
to have a pathogenic variant for a more detailed discussion of what it means for them and their 
families. 
The goal of this study was to assess the effectiveness and satisfaction of this video 
education model to determine if it would be a viable method of delivery of genetic information. A 
pilot study was created in 2019 which analyzed effectiveness of this video through assessment of 
knowledge retention.73 The current study continued data collection of the pilot study, and assessed 
the additional component of patient satisfaction. Individuals who underwent video education were 
compared with individuals who had traditional in-person genetic counseling with a genetic 
counselor. Studies have been published which analyze the use of educational videos in healthcare, 
however, there are limited studies which assess participant knowledge and satisfaction of this 
delivery method.52,53,69 
A major driver of this study was the need to increase access to genetic testing in individuals 
with PDAC. One of the outcomes analyzed was effectiveness of video education. Of the sixty-four 
participants in the study, fifty-nine elected to proceed with genetic testing. This represents an 
overall planned uptake of genetic testing in 89% of participants, 91% in the traditional education 
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group and 88% in the video education group. Therefore, there was no significant difference in 
uptake of genetic testing between groups. This suggests that video education does not reduce 
patients’ understanding of why genetic testing may be relevant for themselves and their families. 
This result is comparable to other research studies that evaluated change in behavior following 
video education. One study trialed the use of animated videos in a pediatric emergency department 
waiting room to provide tips for managing common illnesses at home. Twenty-two of twenty-
seven participants reporting that the video would influence their behavior, correlating to 81.5%.51 
Another study evaluated the use of a genetic counseling educational video for women with ovarian, 
fallopian, and peritoneal carcinomas. Of the total participants, 55% of participants elected to 
pursue genetic testing.53 
Research has shown that limited health literacy makes it difficult for individuals to 
understand health information and make informed decisions, which results in numerous burdens 
on the healthcare system and lack of proper care.55 In this study, 15.6% of individuals were 
identified to have low genetic literacy. This is lower than the average number of individuals in the 
United States with limited health literacy of approximately 33% and the average score on a 
genetics basics questionnaire of 65%.54,56 Probable explanations for this difference include; 
individuals with limited health literacy may not have sought care at a tertiary medical center, are 
located in different geographic regions than was evaluated by this study, declined participation in 
the study, or the sample size was not large enough. A study through the National Institute of Aging 
analyzed the ability of patients to correctly recall health information being orally presented to them 
by a healthcare provider, in relation to the patient’s baseline health literacy. Results of this study 
showed reduction in patient recall of information in individuals with limited health literacy. Mean 
score in the low literacy group was 2.5 and mean score in the adequate literacy group was 4.6.61 
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Given the outcomes of this prior research study, we anticipated that performance on the 
knowledge questionnaire would be influenced by participants’ genetic literacy. The mean 
knowledge score for individuals determined to have low literacy was 5.3 (± 1.2) and those 
determined to have adequate literacy was 5.8 (± 0.87). Data analysis showed that this difference 
was not statistically significant. This unexpected conclusion may be due to the small sample size. 
We hypothesized that participants in video education group would not score differently 
than those in the traditional education group on the knowledge questionnaire. The video was 
designed to cover an abbreviated version of the same information about genetic testing that a 
cancer genetic counselor would address in a traditional counseling session. The mean knowledge 
score for timepoint 1 in the traditional education and video education groups was 5.7 (± 0.99) and 
5.8 (± 0.90), respectively. This showed no statistical significance between knowledge score of both 
groups. Part of the genetic counseling training includes skills to assess patient health literacy and 
adjust the conversation accordingly. Consequently, it is possible that literacy would have a greater 
influence on knowledge score in the video education group. This was not found as the mean 
knowledge score for individuals with low genetic literacy was slightly higher in the video group 
as compared to the traditional education group.  
We anticipated that individuals would have a lower knowledge score on timepoint 2 as 
compared to timepoint 1. The structure of the MDC clinic involves discussion with multiple 
healthcare providers on the day of the appointment, resulting in a substantial amount of 
information being presented to the patient. Given the nature of pancreatic ductal adenocarcinoma, 
it is likely that the majority of these conversations included poor and perhaps devastating news. 
We know that when people are experiencing psychological distress, they have limited ability to 
retain information.74 Therefore, we anticipated their retention of genetics education would be 
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reduced weeks following the initial appointment. The majority of patients in both traditional and 
video education group experienced a reduction in knowledge score at timepoint 2. A smaller group 
of individuals experienced an increase in knowledge score or a knowledge score that stayed the 
same between timepoints. The difference in knowledge retention was not significant between 
education groups, suggesting that patients have the same ability to retain knowledge from a video 
as they do from a genetic counselor. 
The revised study protocol indicated that timepoint 2 should occur four weeks after 
timepoint 1. Timepoint 2 was completed over the phone. Given logistical limitations of being able 
to contact patients over the phone, the interval between timepoints varied between participants. 
Research has shown that knowledge retention decreases as time passed increases.75 Therefore, we 
speculated that increased time between intervals could be correlated with a decrease in knowledge 
score at timepoint 2. A correlation test was performed to assess the association between the 
difference in knowledge score and the length of interval between timepoints. There was no 
significant statistical difference in knowledge score based on interval between timepoints. 
The pilot study for this research sought to analyze the effectiveness of video education for 
genetic testing in individuals with pancreatic cancer. Effectiveness was determined by retention of 
knowledge and uptake of genetic testing between education groups. Preliminary results from the 
pilot study indicated that there was no statistical difference in effectiveness between the traditional 
genetic counseling and video education group.73 This research study continued assessment of 
effectiveness to determine if the statistical outcome would change with a larger sample size. 
Results of this study confirmed that there is no statistical difference in efficacy between groups. 
This study also analyzed the additional component of patient satisfaction regarding receiving video 
education. The ultimate goal of this research is to determine if video education can be used for 
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delivery of genetic information. Consequently, we must determine if video education is both 
effective and satisfactory.  
Satisfaction was determined through administration of the satisfaction questionnaire. The 
satisfaction questionnaire was designed specifically for this study to assess multiple dimensions of 
patient satisfaction. Prior research studies which have evaluated the use of telemedicine show the 
greatest reduction  in satisfaction derived from the absence of body language communication, back 
and forth discussion, and delivery of handouts.68 We therefore anticipated the greatest negative 
response in the video education group for the question, “I wish I had more of an opportunity to ask 
questions about genetic testing.” In order to improve access to genetic information, this educational 
video could be utilized in a setting where genetic counselors are not immediately available. 
Consequently, the greatest limitation of video education would be the inability to engage in a 
discussion of question and answer. The mean satisfaction score for this question was lower in the 
video education as compared to the traditional education group, with a p-value of 0.0537 which 
approaches statistical significance. This suggests a potential limitation of the video education in 
the inability to ask questions after viewing the video. This can be a significant hindrance in the 
ability to make an informed decision about genetic testing and the ability for patients to accurately 
understand what genetic testing means for them and their family. Genetics is a particularly 
complex field and genetic counseling training emphasizes the importance of eliciting and 
addressing questions throughout the genetic counseling appointment. Potential research to address 
this issue is discussed in the future directions section of this paper.  
While lack of ability to ask questions raises doubt as to whether or not patients are properly 
informed to make a genetic testing decision, this concern was in part addressed in another portion 
of the satisfaction questionnaire. One statement in this questionnaire was “Based on the 
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information presented [in the video/by the genetic counselor], I do not feel comfortable making a 
decision about getting genetic testing.” The mean score for this question was 1.6 (± 0.77) and 1.9 
(± 0.96) for the video education and traditional education groups, respectively. This is interpreted 
with the trend towards disagreement with the statement, indicating that people did feel comfortable 
making a decision about the testing after receiving genetics education. There was no statistical 
difference in this analysis between tradition and video education groups. These findings suggest 
that while many people in the video education group wished they had more of an opportunity to 
ask questions, they still felt comfortable to make a decision about genetic testing. 
All other questions in the satisfaction questionnaire were analyzed. There was no 
significant difference in response to these questions individually and the total satisfaction score 
between education groups. Overall, the analyses from part 2 of this research study reveals that 
video education is a satisfactory method of delivering genetics education about genetic testing for 
pancreatic cancer. 
Telemedicine has long been a component in health information delivery. However, with 
alternative methods of using technology for health education, the results of this study are both 
contributory and novel information regarding the use of pre-recorded videos for delivery of genetic 
information for genetic testing in individuals with PDAC.  
3.4.1 Study Limitations and Future Directions 
Perhaps the biggest limitation of this study is lack of analysis regarding the effectiveness 
of delivery of genetic testing results in the video education and traditional education groups. The 
goal of this study was to determine if video education is both an effective and satisfactory method 
to deliver information about genetic testing so that individuals with pancreatic ductal 
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adenocarcinoma can make an informed decision about whether or not to pursue testing. However, 
this study did not evaluate if video education is an effective method for the continuation of care 
through proper receipt of genetic testing results.  
In the traditional education group, two genetic counselors who specialize in gastrointestinal 
cancers were in charge of tracking and returning genetic testing results to patients. All results were 
returned to patients in a timely manner over the phone regardless of whether the results were 
negative, VUS, or pathogenic variant.  The result disclosure was documented in the patients’ 
electronic medical record (EMR) as a telephone encounter, the results were scanned into the 
patients’ EMR, and the patients were mailed a copy of their results and a summary letter. In the 
video education group, the medical oncologist, surgical oncologist, or a member of their care team 
was in charge of tracking and returning genetic testing results to patients.  Although these 
individuals received verbal training, written protocols, and disclosure templates from the genetic 
counselors so that result disclosure would mirror that of the genetic counselors, these processes 
were not utilized.  Result disclosure was not documented in the EMR and the study team has no 
means of determining if or when patients were notified of their results, aside from the individuals 
with a pathogenic variant who were referred for counseling. We do not have sufficient information 
to determine reason for lack of proper results return.  
While return of results with a pathogenic variant is most important for immediate impact 
on the affected individual and their family, knowledge of a negative result or VUS is still essential. 
A negative result is pertinent information for family members in terms of recommendations for 
pancreatic cancer surveillance and genetic testing guidance should additional family members 
develop cancer. A VUS is important for the same reasons as a negative result in addition to the 
potential for this variant to be reclassified as pathogenic. Consequently, the genetic testing process 
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is insufficient when all results are not returned. This lack of proper results return in the video 
education group represents significant limitations to the utility of this delivery method for genetic 
testing education. If this method were to be utilized in future at other healthcare locations, either a 
different protocol would need to be established in order to ensure proper results return or 
checkpoints would need to be in place to ensure that the original protocol is followed. Genetic 
counseling assistants may be a useful asset to facilitate the administrative and logistic aspects of 
proper results return. 
Another limitation resulting in insufficient completion of the genetic testing process, is the 
lack of proper follow-up for individuals identified to have a pathogenic variant in the video 
education group. The video provides only brief education about genetic testing in a 5-minute power 
point presentation with recorded audio. The video is not designed to be a comprehensive discussion 
of cancer risks, surveillance and/or surgical guidelines, and familial risk for individuals with a 
pathogenic variant identified through testing. Consequently, participants should have a follow-up 
discussion with a genetic counselor about implications of the specific variant identified. 
Participants who do not have a follow-up appointment receive incomplete genetic counseling and 
therefore are not properly informed of all the implications of the variant.  
In the video education group pathogenic variants were identified in MUTYH(x2), 
CHEK2(x2), and BRCA2. Only two of these five participants in the video group had their follow-
up consultation with a genetic counselor. This means that three individuals and their families are 
not properly informed about the implications of their pathogenic variant. Limitations of this study 
prevent us from knowing whether or not they received genetics education from an outside source, 
e.g., oncologist, primary care physician, or genetic counselor at an external institution. All 
participants in the traditional genetic counseling group received a follow-up call or appointment 
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after return of results, which included a detailed discussion of implications of the pathogenic 
variant, if applicable. This imbalance in care between the video education and traditional genetic 
counseling group represents a drawback in the video education method in providing patients with 
comprehensive and complete genetic testing results education. A future direction for this study 
could be to analyze patient actions following a result which revealed a pathogenic variant, possibly 
through administration of a follow-up questionnaire for patients with a positive result ascertaining 
their subsequent plans for action. 
Another major limitation of this study was the ability to guess the correct answer on the 
knowledge questionnaire. Data analysis showed that while there was a reduction in knowledge 
score between timepoint 1 and timepoint 2, the change was not large enough to be statistically 
significant. However, when speaking with patients over the phone to administer the knowledge 
questionnaire at timepoint 2, the vast majority of participants admitted they did not remember the 
answer to any of the statements or that they didn’t remember watching the video/speaking with 
the genetic counselor. These participants subsequently answered the knowledge questionnaire 
based on common sense or random guess, as opposed to memory from their initial MDC 
appointment. The knowledge questionnaire consists of True and False statements. Therefore, there 
is a 50% chance that someone guessing on the questions without remembering their genetics 
education could guess correct. While the ability to guess on the knowledge questionnaire was also 
a factor in timepoint 1, patients reported their inability to remember the genetics education with 
much greater frequency in timepoint 2. This provides significant limitation to the validity of 
knowledge retention assessment. Additionally, this reduces efficacy of both methods of delivering 
genetics education since most participants did not remember the information presented in the 
genetics education.  
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One possibility for this inability to recall the conversation, could be the circumstances of 
receiving the information. The MDC visits are typically the first time patients are receiving details 
of their diagnosis, outcome for survival, and information about the impact on quality of life. Given 
the mortality of PDAC, this is typically distressing news. Following the delivery of this news, the 
patients meet with multiple providers each presenting their agenda of recommendations and care 
plans. Multiple fields of research show a reduction in ability to retain information in times of stress, 
shock, and information overload.74  
One area of future research to address this concern could be to assess the efficacy of 
providing genetics education outside of the MDC appointment. This could entail meeting with the 
genetic counselor/viewing the video at an appointment after the initial MDC clinic. This would 
allow time for the patient to grasp the diagnosis and breadth of information presented by other 
providers in the multidisciplinary team before hearing information about genetics. While time is 
one of the major reasons for employing this alternative method of genetics education, patients with 
PDAC will typically start treatment and care immediately. Therefore, patients will likely return to 
the hospital very soon after their MDC appointment when genetics education could be delivered. 
One limitation of this method would be that some individuals decide to seek care at a more 
geographically local hospital.  
Another potential barrier to administration of this video education tool in future clinics and 
hospitals lies in the logistics of viewing and playing the video. In this research study, the study 
coordinator brought the tablet containing the genetics education video into each of the patient 
rooms, set up and played the video for each participant, waited for conclusion of the 5-minute 
video, and then retrieved the tablet to repeat the process with the next patient. While this is a simple 
task, in an MDC clinic of multiple specialty providers with their own agenda and high volume of 
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patients to attend, this raises the dilemma of who will administer the video. This may also be a 
suitable role for a genetic counseling assistant. A solution to this issue may be more easily solved 
in some locations versus others depending on the available resources. For example, some clinics 
may have a medical assistant who can administer the video for each patient or some clinics may 
have a tablet already set in each patient room to which the video can be uploaded with easy 
instructions for the patient to play the video themselves. However, neither of these are currently 
available options in the Pittsburgh Hillman Cancer Center and UPMC Presbyterian Hospital 
raising suspicion that these limitations may also be present in other locations.  
Another limitation of this study inherently exists in the study design; the two groups do not 
experience each other’s version of genetics education. It is plausible that if the video education 
group were to have understood that the traditional education group received more comprehensive 
genetics education and had the opportunity for question/answer discussion, then the participants 
in the video education group would have ranked lower on the satisfaction survey. However, this 
limitation may have been ruled out by the chance that this concept could apply in an opposite 
manner. The MDC appointment is several hours long with multiple providers presenting a vast 
amount of information. Therefore, patients may actually be more satisfied with the brief and non-
interactive video education than they would with a more lengthy presentation by a genetic 
counselor. 
3.4.2 Conclusion 
As national guidelines for genetic testing change and the subsequent demand for genetic 
counselors to carry out this process increases, new methods of genetic education delivery must be 
explored to adapt to the currently limited supply of genetic counselors. Already existing practices 
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in telehealth pave the way for the use of pre-recorded video education. This study was a 
continuation of a novel pilot study which addressed the efficacy of the use of video education to 
deliver information about genetic testing for individuals with PDAC. The results of this study 
validate the pilot study by demonstrating no significant difference in retention of knowledge 
between the traditional genetic counseling group and video education group. This study 
additionally evaluated patient satisfaction of video education. Minimal research currently exists to 
evaluate patient satisfaction in a non-interactive form of virtual genetics education. The results of 
this study conclude that there is no significant difference in patient satisfaction between the 
traditional education and video education group. The sample size for this portion of the study was 
relatively small and further evaluation may be necessary to determine the validity of this result. 
The findings of this study suggest that video education is both an effective and satisfactory method 
of delivering genetics testing information to individuals with PDAC. This is an important finding 
given the rapidly developing nature of genetic discovery and subsequent need for alternative 
methods of genetic education to facilitate utilization of this information by patients and their 
families.  
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4.0 Research Significance to Genetic Counseling and Public Health 
Genetics is a unique area of medicine that can have significant and complex impacts on an 
individual’s health. While most healthcare providers have general knowledge about genetics, 
research has found that many health care providers feel unprepared to discuss genetic information 
with their patients.76,77 As genetic discoveries continue to be made at a rapid rate and genetics 
becomes more integrated into standard clinical care, the need for health care professionals who 
specialize in genetics has become paramount. Genetic counselors are specially trained to relay 
genetic information to patients with inclusion of detailed discussions of risk assessment, family 
history evaluation, diagnostic testing, screening and surveillance, genetic testing, and psychosocial 
implications. Current barriers exist which limit access to genetic counselors for all individuals in 
need of their services. This predicament has led to the exploration of alternative service delivery 
models.  
Given the lethality of pancreatic cancer and the potential implications for both the affected 
individual and their family members, it is imperative to increase access to genetic testing to all 
individuals with PDAC in a timely manner. This study explored the use of video education as a 
satisfactory alternative delivery model of information about genetic testing through assessment of 
knowledge retention and patient satisfaction.  
While traditional in-person genetic counseling remains necessary for certain discussions, 
generalized video education may be an appropriate approach for more routine genetics topics such 
as genes, chromosomes, and genetics of cancer. The use of a video for these genetic concepts 
would permit the limited number of genetic counselors to focus their time and availability on the 
more complex and personalized indications and discussions.  
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Genetic testing for pancreatic cancer is both a recommended and uniquely important area 
of cancer genetic counseling. NCCN and ASCO recommend genetic testing for all individuals with 
pancreatic cancer regardless of any other factors.2,3 This specification lends itself easily to a 
standardized discussion of pre-test counseling. At UPMC, not all individuals with pancreatic 
cancer are referred for genetic testing or follow-through with the recommendation to speak with a 
genetic counselor. Therefore, the use of video education to present information about genetic 
testing during an oncology appointment would increase access to genetic testing while adapting to 
the limited number of genetic counselors. The results of this study suggest that video education is 
both a satisfactory and effective way of delivering information about genetic testing and therefore 
could be successfully utilized in genetic counseling practice.  
The three core functions of public health include assessment, policy development, and 
assurance. This study focuses on the functions of policy development and assurance. The public 
health goal of expanding genetic testing to all individuals with PDAC is to reduce illness and death 
due to pancreatic cancer. Current plans in place do not sufficiently support this goal due to limited 
resources. Policy development focuses on creating plans to support community health efforts. 
UPMC recognized the limitations in access to genetic testing and proposed an alternative method 
of delivering genetic information to address this issue through the use of video education. Findings 
from this study suggest that video education is an appropriate system to be used in development 
of a new policy and procedure for genetic testing education in individuals with PDAC. 
Assurance focuses on linking people to the services they need and ensuring the 
effectiveness, accessibility, and quality of these services. Results of this study suggest that video 
education is a successful method of delivery information about genetic testing. Future work could 
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include implementing video education for PDAC in other healthcare institutions. Ultimately, the 
goal is to improve access to genetic testing for all individuals with PDAC. 
This study provides valuable information about the utility of video education to deliver 
genetic testing information for pancreatic cancer. If this method of alternative service delivery 
were to be employed in general genetics practice, then policies would need to be established to 
ensure proper access to genetic counseling; namely, a plan for return of all results and assurance 
of completion of the appropriate post-test counseling. Additional safeguards would need to be in 
place to monitor the use of video education to establish that it does not result in a deviation from 
appropriate access to test results and relevant genetic counseling services. While this study focused 
on the use of video education in genetic counseling, employment of this method of health education 
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Appendix A.1 Rapid Estimate of Adult Literacy- Genetics (REAL-G) 
 
REAL-G Short Form 
 
You can quickly determine your patient’s genetic literacy with this oral reading and recognition test, 
known as the Rapid Estimate of Adult Literacy in Genetics (REAL-G).  It measures a patient’s ability to 
pronounce 8 words used frequently in genetics.  To use REAL-G, follow these 5 steps: 
 











2. As the patient to read aloud as many words as they can, beginning with the first word.  When they 
come to a word they cannot read, tell them to do the best they can or say “blank,” and then go on to the 
next word on the list. 
 
If the patient takes longer than five seconds to read a word, prompt them to move on by saying “blank,” 
and pointing to the next word on the list.  If the patient begins to miss every word, as her to pronounce 
only those words they know. 
 
3. On your copy of the lists, keep score of the patient’s answers.  Next to each correctly pronounced 
word, write a plus sign (+).  After each word that was not attempted or was mispronounced, write a 
minus sign (-). 
 
4. This total is the patient’s raw score. 
 




Adapted from instructions from Davis, T., Crouch, M. & Long, S. (1993). Rapid Estimate of Adult Literacy in Medicine (REALM). 
Shreveport, LA: Louisiana State University Medical Center. 
 
Erby LH, Roter D, Larson S, Cho J. 2007.  The rapid estimate of adult literacy in genetics (REAL-G): A means to assess literacy 








Please read each word below out loud to the best of your ability.  If you are not sure how to say a word, 

























Appendix A.2 Pancreatic Cancer Genetics Knowledge Questionnaire 
 
Pancreatic Cancer Genetics Knowledge Questionnaire 
 
 Please answer all items even if you are unsure of the answer.  True False 
1 About 20% of people with pancreatic cancer have a mutation, or 
harmful change, in a gene that increases their risk for pancreatic 
cancer. 
  
2 When a gene associated with pancreatic cancer is doing its job, it 
helps prevent cancer from forming. 
  
3 Genetic testing looks for mutations, or harmful changes, in genes.   
4 My doctors may be able to use genetic testing results in my 
pancreatic cancer treatment. 
  
5 If I have a mutation in a pancreatic cancer gene, my family 
members should consider genetic testing. 
  
6 Genetic testing for pancreatic cancer involves looking for a 
mutation in only one gene. 
  































Appendix A.3 Patient Satisfaction Survey 
 
VIDEO GROUP 
Please tell us your opinion on the information about genetic testing that was just presented to you in the 
video. For each statement, please rate how much you agree or disagree using one of these options: 
strongly disagree, disagree, neutral, agree, and strongly agree.  
 Strongly 
Disagree 
Disagree Neutral Agree Strongly 
Agree 
1) The information presented about genetic 
testing was difficult to follow 
     
2) The information presented about genetic 
testing felt relevant to my diagnosis 
     
3) The information provided explained the 
purpose of genetic testing for a person 
with pancreatic cancer 
     
4) Based on the information presented in 
the video, I do not feel comfortable 
making a decision about getting genetic 
testing 
     
5) I trust that the information about genetic 
testing presented in the video is accurate  
     
6) I wish I had more of an opportunity to 
ask questions about genetic testing 
     
7) I would recommend the video to other 
people with pancreatic cancer as a way 
to learn about genetic testing 
















Please tell us your opinion on the information about genetic testing that was just presented to you by the 
genetic counselor. For each statement, please rate how much you agree or disagree using one of these 
options: strongly disagree, disagree, neutral, agree, and strongly agree. 
 Strongly 
Disagree 
Disagree Neutral Agree Strongly 
Agree 
1) The information presented about genetic 
testing was difficult to follow 
     
2) The information presented about genetic 
testing felt relevant to my diagnosis 
     
3) The information provided explained the 
purpose of genetic testing for a person 
with pancreatic cancer  
     
4) Based on the information presented by 
the genetic counselor, I do not feel 
comfortable making a decision about 
getting genetic testing 
     
5) I trust that the information about genetic 
testing presented by the genetic 
counselor is accurate 
     
6) I wish I had more of an opportunity to 
ask questions about genetic testing 
     
7) I would recommend speaking with a 
genetic counselor to other people with 
pancreatic cancer as way to learn about 
genetic testing 
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Appendix B  






















AGE DIFFERENCE BETWEEN EDUCATION GROUPS 
 




    Prob > |z| =   0.3400
             z =   0.954
Ho: v2(v1==1) = v2(v1==2)
adjusted variance       5536.76
                               
adjustment for ties       -9.90
unadjusted variance     5546.67
    combined         64        2080        2080
                                               
           2         32         969        1040
           1         32        1111        1040
                                               
          v1        obs    rank sum    expected
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
   1-sided Fisher's exact =                 0.098
           Fisher's exact =                 0.196
                  40.0       24.0        64.0 
     Total          40         24          64 
                                             
                  20.0       12.0        32.0 
         2          23          9          32 
                                             
                  20.0       12.0        32.0 
         1          17         15          32 
                                             
     group           1          2       Total
                      sex
                      
  expected frequency  
      frequency       
                      
  Key                 
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LITERACY DIFFERENCE BETWEEN EDUCATION GROUPS 
 
 
TIMEPOINT 1 KNOWLEDGE BY LITERACY LEVEL 
 
   1-sided Fisher's exact =                 0.366
           Fisher's exact =                 0.732
                   10.0       54.0        64.0 
      Total          10         54          64 
                                              
                    5.0       27.0        32.0 
      video           6         26          32 
                                              
                    5.0       27.0        32.0 
traditional           4         28          32 
                                              
      group           1          2       Total
                    literacy
                      
  expected frequency  
      frequency       
                      
  Key                 
                      
    Prob > |z| =   0.2284
             z =  -1.204
Ho: knowle~e(literacy==low literacy) = knowle~e(literacy==no low lit)
adjusted variance       2650.11
                               
adjustment for ties     -274.89
unadjusted variance     2925.00
    combined         64        2080        2080
                                               
  no low lit         54        1817        1755
low literacy         10         263         325
                                               
    literacy        obs    rank sum    expected
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
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TIMEPOINT 2 KNOWLEDGE BY LITERACY LEVEL 
 
 




    Prob > |z| =   0.4911
             z =  -0.689
Ho: knowle~e(literacy==low literacy) = knowle~e(literacy==no low lit)
adjusted variance       1164.99
                               
adjustment for ties     -114.26
unadjusted variance     1279.25
    combined         50        1275        1275
                                               
  no low lit         43        1120      1096.5
low literacy          7         155       178.5
                                               
    literacy        obs    rank sum    expected
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
    Prob > |z| =   0.7403
             z =  -0.331
Ho: knowle~e(group==traditional) = knowle~e(group==video)
adjusted variance       5025.40
                               
adjustment for ties     -521.27
unadjusted variance     5546.67
    combined         64        2080        2080
                                               
       video         32      1063.5        1040
 traditional         32      1016.5        1040
                                               
       group        obs    rank sum    expected
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
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TIMEPOINT 2 KNOWLEDGE BY EDUCATION GROUP 
 
DIFFERENCE IN KNOWLEDGE SCORE BETWEEN TIMEPOINT 1 AND TIMEPOINT 2 
(ALL) 
 
    Prob > |z| =   0.7901
             z =   0.266
Ho: knowle~e(group==traditional) = knowle~e(group==video)
adjusted variance       2384.17
                               
adjustment for ties     -233.83
unadjusted variance     2618.00
    combined         50        1275        1275
                                               
       video         22         548         561
 traditional         28         727         714
                                               
       group        obs    rank sum    expected
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
    Prob > |z| =   0.1359
             z =   1.491
Ho: Timepoint1 = Timepoint2
adjusted variance      10251.63
                               
adjustment for zeros    -204.75
adjustment for ties     -274.88
unadjusted variance    10731.25
         all         50        1275        1275
                                               
        zero         13          91          91
    negative         15         441         592
    positive         22         743         592
                                               
        sign        obs   sum ranks    expected
Wilcoxon signed-rank test
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DIFFERENCE IN KNOWLEDGE SCORE BETWEEN TIMEPOINT 1 AND TIMEPOINT 2 
(TRADITIONAL) 
 
DIFFERENCE IN KNOWLEDGE SCORE BETWEEN TIMEPOINT 1 AND TIMEPOINT 2 
(VIDEO) 
 
    Prob > |z| =   0.4096
             z =   0.825
Ho: Timepoint1 = Timepoint2
adjusted variance       1853.13
                               
adjustment for zeros     -22.75
adjustment for ties      -52.63
unadjusted variance     1928.50
         all         28         406         406
                                               
        zero          6          21          21
    negative          9         157       192.5
    positive         13         228       192.5
                                               
        sign        obs   sum ranks    expected
Wilcoxon signed-rank test
    Prob > |z| =   0.2094
             z =   1.255
Ho: Timepoint1 = Timepoint2
adjusted variance        892.50
                               
adjustment for zeros     -35.00
adjustment for ties      -21.25
unadjusted variance      948.75
         all         22         253         253
                                               
        zero          7          28          28
    negative          6          75       112.5
    positive          9         150       112.5
                                               
        sign        obs   sum ranks    expected
Wilcoxon signed-rank test
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    Prob > |t| =       0.4211
Test of Ho: scorechange and interval are independent
Spearman's rho =       0.1163
 Number of obs =      50
    Prob > |z| =   0.5206
             z =   0.642
Ho: satisf~n(group==traditional) = satisf~n(group==video)
adjusted variance        293.24
                               
adjustment for ties      -40.42
unadjusted variance      333.67
    combined         25         325         325
                                               
       video         14         171         182
 traditional         11         154         143
                                               
       group        obs    rank sum    expected
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
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SATISFACTION SCORE BY EDUCATION GROUP (QUESTION 2) 
 
 




    Prob > |z| =   0.8577
             z =  -0.179
Ho: satisf~n(group==traditional) = satisf~n(group==video)
adjusted variance        279.89
                               
adjustment for ties      -53.77
unadjusted variance      333.67
    combined         25         325         325
                                               
       video         14         185         182
 traditional         11         140         143
                                               
       group        obs    rank sum    expected
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
    Prob > |z| =   0.3159
             z =  -1.003
Ho: satisf~n(group==traditional) = satisf~n(group==video)
adjusted variance        254.49
                               
adjustment for ties      -79.18
unadjusted variance      333.67
    combined         25         325         325
                                               
       video         14         198         182
 traditional         11         127         143
                                               
       group        obs    rank sum    expected
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
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SATISFACTION SCORE BY EDUCATION GROUP (QUESTION 4) 
 
 




    Prob > |z| =   0.4162
             z =   0.813
Ho: satisf~n(group==traditional) = satisf~n(group==video)
adjusted variance        275.66
                               
adjustment for ties      -58.01
unadjusted variance      333.67
    combined         25         325         325
                                               
       video         14       168.5         182
 traditional         11       156.5         143
                                               
       group        obs    rank sum    expected
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
    Prob > |z| =   0.3279
             z =  -0.978
Ho: satisf~n(group==traditional) = satisf~n(group==video)
adjusted variance        251.02
                               
adjustment for ties      -82.65
unadjusted variance      333.67
    combined         25         325         325
                                               
       video         14       197.5         182
 traditional         11       127.5         143
                                               
       group        obs    rank sum    expected
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
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SATISFACTION SCORE BY EDUCATION GROUP (QUESTION 6) 
 
 




    Prob > |z| =   0.0537
             z =   1.929
Ho: satisf~n(group==traditional) = satisf~n(group==video)
adjusted variance        292.60
                               
adjustment for ties      -41.07
unadjusted variance      333.67
    combined         25         325         325
                                               
       video         14         149         182
 traditional         11         176         143
                                               
       group        obs    rank sum    expected
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
    Prob > |z| =   0.9027
             z =  -0.122
Ho: satisf~n(group==traditional) = satisf~n(group==video)
adjusted variance        267.57
                               
adjustment for ties      -66.09
unadjusted variance      333.67
    combined         25         325         325
                                               
       video         14         184         182
 traditional         11         141         143
                                               
       group        obs    rank sum    expected
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
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    Prob > |z| =   0.1048
             z =   1.622
Ho: satisf~n(group==1) = satisf~n(group==2)
adjusted variance        330.84
                               
adjustment for ties       -2.82
unadjusted variance      333.67
    combined         25         325         325
                                               
           2         14       152.5         182
           1         11       172.5         143
                                               
       group        obs    rank sum    expected
Two-sample Wilcoxon rank-sum (Mann-Whitney) test
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Appendix C  
A complete list of genes analyzed as a part of Invitae’s Detect Study for Hereditary 
Pancreatic Cancer. This panel includes 84 genes associated with pancreatic cancer and other types 
of cancers. 
AIP, ALK, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, 
CASR, CDC73, CDH1, CDK4, CDKN1B, CDKNIC, CDKN2A, CEBPA, CHEK2, CTNNA1, 
DICER1, DIS3L2, EGFR, EPCAM*, FH, FLCN, GATA2, GPC3, GREM1*, HOXB13, HRAS, KIT, 
MAX, MEN1, MET, MITF**, MLH1, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, 
PALB2, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD50, 
RAD51C, RAD51D, RB1, RECQL4, RET, RUNX1, SDHA**, SDHAF2, SDHB, SDHC, SDHD, 
SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TERC, TERT, TMEM127, TP53, 
TSC1, TSC2, VHL, WRN, WT1 
 
*Deletion/duplication analysis only  
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